Cardinal Health

Cardinal Health Specialty Solutions is a tech-enabled healthcare services business that helps specialty providers and biopharma companies improve the lives of patients through the delivery of pharmaceutical distribution, data, technology and commercial solutions. Cardinal Health Specialty Solutions serves a network of more than 10,000 specialty physician practices and clinics and supports more than 300 biopharma companies across the U.S. Learn more at

Connect with us:

Latest from Cardinal Health

Adding Drug Costs to the Clinical Support Equation

June 23, 2022

Amy Valley, PharmD, vice president of clinical strategy and technology solutions, Cardinal Health Specialty Solutions, discusses the Decision Path, a clinical support tool designed to inform oncology providers about drug costs along with clinical information, all embedded into the electronic health record workflow.

Cardinal Health’s Aklilu Tedla on CAR T-Cell Administration Outside of the Hospital

June 08, 2022

Moving chimeric antigen receptor (CAR) T-cell therapies outside of the hospital will bring training and safety challenges, said Aklilu Tedla, vice president, insights and engagement, regulatory science, cell and gene, Cardinal Health.

Cardinal Health’s Aklilu Tedla Discusses Logistics of Allogeneic CAR T-Cell Therapies

May 31, 2022

Allogeneic, or off-the-shelf, chimeric antigen receptor (CAR) T-cell therapies will bring new logistical challenges, said Aklilu Tedla, vice president, insights and engagement, regulatory science, cell and gene, Cardinal Health.

Dr Sonia Oskouei on Managed Care’s Impact After Rollout of Adalimumab Biosimilars

May 16, 2022

While 2023 is a big year with at least 7 adalimumab biosimilars expected to come to market, 2024 will be even more important because all the products will be on the market and formulary decisions can be made, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.

Payers, Value-based Care Policies Impact Biosimilar Adoption, Cardinal Health Report Finds

February 08, 2022

Cardinal Health's report, “2022 Biosimilars Report: The U.S. Journey and Path Ahead,” outlines how biosimilars will move beyond their comfort zones in oncology and rheumatology and more boldly into therapeutic areas such as ophthalmology and diabetes care.

Stronger Community Connections, Fewer Barriers Are Keys to Better Trials

December 19, 2021

Bruce A. Feinberg, DO, of Cardinal Health Specialty Solutions, leads a panel discussion on how far randomized clinical trials have come, how they could be better, and how using real-world evidence could make research more representative of the population.

What's Next After OCM? Possibly a Gap and Something Mandatory, Experts Predict

September 25, 2021

With the Oncology Care Model (OCM) slated to end in 2022, the successor model is still not in place. According to panelists, there is likely going to be a gap after OCM ends and the new model begins, but more importantly, practices should prepare for the new model to be mandatory.